论文部分内容阅读
预防乙型肝炎病毒感染现有一种安全,高效与获得批准的疫苗。乙型肝炎是一种常见而严重的疾病,美国每年发病200万例。75％病人临床症状轻微或不显,25％出现黄疸,5％需住院治疗,0.1％死于暴发性肝炎;被感染的病人6—10％成为慢性携带者。美国600万—800万携带者中近25％可发展为慢性肝炎,每年约4,000例死于肝硬变。此外,每年有1—2％的携带者由乙型肝炎导致肝细胞癌而死亡。乙型肝炎疫苗由经生物化学与生物物理方法灭活的人乙型肝炎表面抗原(HBsAg)微粒所组成。HBsAg是用筛选出的健康慢性
Prevention of Hepatitis B Virus There is a safe, efficient and approved vaccine available. Hepatitis B is a common and serious disease that affects 2 million Americans each year. 75% of patients with mild or no clinical symptoms, 25% jaundice, 5% required hospitalization, 0.1% died of fulminant hepatitis; infected patients 6-10% become chronic carriers. Nearly 25% of the 6 million-8 million carriers in the United States can develop chronic hepatitis and about 4,000 die of cirrhosis each year. In addition, 1-2% of carriers each year die from hepatitis B-causing hepatocellular carcinoma. Hepatitis B vaccine is composed of human hepatitis B surface antigen (HBsAg) particles inactivated by biochemical and biophysical methods. HBsAg is screened out healthy and chronic